Advertisement


Kevin C. Oeffinger, MD, on Controversies in Breast Cancer Screening Strategies

2016 NCCN Annual Conference (1)

Advertisement

Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.



Related Videos

Hepatobiliary Cancer

Anne Covey, MD, on Hepatocellular Carcinoma: Guideline Updates for Locoregional Treatment

Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.

Pain Management

Judith Paice, PhD, RN, on Managing Cancer Pain: Strategies for Prescribing Opioids

Judith Paice, PhD, RN, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses strategies for safe opioid prescribing: making a comprehensive assessment, stratifying risk, using universal precautions, and educating practitioners on safe storage and disposal.

Symptom Management
Survivorship

Joseph B. Narus, DNP, GNP-BC, ANP, on Sexual Function in Survivors: Guideline Update

Joseph B. Narus, DNP, GNP-BC, ANP, of Memorial Sloan Kettering Cancer Center, discusses the impact of cancer treatment on men’s sexual health, and treatment options to improve erectile function.

Leukemia

Jeffrey Jones, MD, MPH, on Chronic Lymphocytic Leukemia: Optimizing Treatment With New Agents

Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.

Lung Cancer

Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease

Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.

Advertisement

Advertisement




Advertisement